MedTrace Logo

Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

NCT02430363 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2016-02-24

No results posted yet for this study

Summary

It is known that after application of MK-3475 activated PD -1 negatively regulates the activation of T cells through suppression of the path of PI3K / Akt.

This study will identify the effectiveness of oral inhibitors of PI3K / Akt pathway in comparison with MK-3475 (pembrolizumab).

Conditions

Interventions

DRUG

MK - 3475

Administered Intravenously

BIOLOGICAL

Suppressor of the PI3K/Akt pathways

Capsules orally with food

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • NCRI Clinical Studies Groups

    collaborator UNKNOWN

  • ECCO - the European CanCer Organisation

    collaborator UNKNOWN

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Medical Research Council

    lead OTHER_GOV

Principal Investigators

  • Jann Lee, PhD · MRC Clinical Trials Unit

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2016-01-31
Completion
2018-06-30

Countries

  • United States
  • Belgium
  • Germany
  • Italy
  • Poland
  • Russia
  • Spain
  • Switzerland
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02430363 on ClinicalTrials.gov